Sangamo BioSciences (SGMO) PT Raised to $30 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Sangamo BioSciences (SGMO) PT Raised to $33 at Jefferies
February 23, 2018 8:58 AM ESTJefferies raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $33.00 (from $18.00) while maintaining a Buy rating.
... MoreSangamo BioSciences (SGMO) PT Raised to $35 at JPMorgan
February 23, 2018 7:24 AM ESTJPMorgan raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $35.00 (from $11.00) while maintaining a Overweight rating.
... MoreSangamo BioSciences (SGMO) PT Raised to $32 at Piper Jaffray, Remains Positive Citing Broadening Platform
February 22, 2018 4:26 PM ESTPiper Jaffray raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $32.00 (from $25.00) while maintaining a Overweight rating.
... MoreSangamo BioSciences (SGMO) PT Raised to $39 at Wells Fargo
February 22, 2018 12:23 PM ESTWells Fargo raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $39.00 (from $30.00) while maintaining a Outperform rating.
The analyst likes the company's competitive advantage in gene-editing, which is attributed to years of experience with single loci targeting and suspects it should be... More
Sangamo Therapeutics (SGMO) Tops Q4 EPS by 3c
February 22, 2018 7:22 AM ESTSangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.15), $0.03 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $13.1 million versus the consensus estimate of $11.43 million.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
... More